NEUROENDOCRINE CANCER OF THE PROSTATE METASTATIC

This adverse event was reported 13 times

These drugs are most commonly taken by patients reporting NEUROENDOCRINE CANCER OF THE PROSTATE METASTATIC:

# Drug Count
0 ABIRATERONE 1
1 ABIRATERONE ACETATE 1
2 APALUTAMIDE 1
3 DAROLUTAMIDE 1
4 DOCETAXEL 1
5 DOCETAXEL ANHYDROUS 1
6 PREDNISONE 1
See all common drugs associated with NEUROENDOCRINE CANCER OF THE PROSTATE METASTATIC

NEUROENDOCRINE CANCER OF THE PROSTATE METASTATIC is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 DAROLUTAMIDE 1 0.0002
1 APALUTAMIDE 1 0.0001
2 ABIRATERONE ACETATE 1 0.0000
3 DOCETAXEL 1 0.0000
4 DOCETAXEL ANHYDROUS 1 0.0000
5 PREDNISONE 1 0.0000
See all drugs enriched for association with NEUROENDOCRINE CANCER OF THE PROSTATE METASTATIC

These drug classes are most commonly taken by patients reporting NEUROENDOCRINE CANCER OF THE PROSTATE METASTATIC:

# Drug class Count
0 Corticosteroid [EPC] 1
1 Microtubule Inhibitor [EPC] 1
See all common drug classes associated with NEUROENDOCRINE CANCER OF THE PROSTATE METASTATIC

NEUROENDOCRINE CANCER OF THE PROSTATE METASTATIC is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Microtubule Inhibitor [EPC] 1 0.0000
1 Corticosteroid [EPC] 1 0.0000
See all drug classes enriched for association with NEUROENDOCRINE CANCER OF THE PROSTATE METASTATIC